Mayne Pharma Agrees to A$604M Richter Takeover
Hungarian pharmaceutical company Gedeon Richter has agreed to acquire all of Australian drugmaker Mayne Pharma for A$6.40 per share in cash, valuing the company’s equity at about A$604 million. The offer is a 99.4% premium to Mayne’s November 16 closing price, and Mayne’s board unanimously recommends shareholders approve the deal, subject to the absence of a better offer and a favorable independent expert assessment. The acquisition is fully funded from Richter’s internal cash and requires regulatory, court and shareholder approvals, as well as completion of Mayne’s planned A$55.5 million sale of its international business to Evaris Pharma. Richter says Mayne’s U.S. presence and women’s health and dermatology portfolios would support its expansion in those areas; the proposal follows an earlier, unsuccessful takeover attempt by Cosette Pharmaceuticals.






